We will be contrasting the differences between Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Rafael Holdings Inc. (NYSEAMERICAN:RFL) as far as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aimmune Therapeutics Inc.||N/A||0.00||210.75M||-3.00||0.00|
|Rafael Holdings Inc.||4.46M||44.49||3.28M||-0.03||0.00|
Table 1 shows the top-line revenue, earnings per share and valuation for Aimmune Therapeutics Inc. and Rafael Holdings Inc.
Table 2 represents Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Rafael Holdings Inc. (NYSEAMERICAN:RFL)’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Aimmune Therapeutics Inc.||0.00%||-67.2%||-59.2%|
|Rafael Holdings Inc.||-73.54%||-3.1%||-2.6%|
Aimmune Therapeutics Inc.’s Current Ratio and Quick Ratio are 7 and 7 respectively. The Current Ratio and Quick Ratio of its competitor Rafael Holdings Inc. are 46.1 and 46.1 respectively. Rafael Holdings Inc. therefore has a better chance of paying off short and long-term obligations compared to Aimmune Therapeutics Inc.
Insider & Institutional Ownership
Roughly 83.3% of Aimmune Therapeutics Inc. shares are held by institutional investors while 39.4% of Rafael Holdings Inc. are owned by institutional investors. About 0.1% of Aimmune Therapeutics Inc.’s share are held by insiders. Insiders Comparatively, held 1.3% of Rafael Holdings Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Aimmune Therapeutics Inc.||2.14%||5.36%||0.16%||-11.91%||-24.45%||3.6%|
|Rafael Holdings Inc.||-0.31%||4.22%||96.21%||70.78%||0%||102.65%|
For the past year Aimmune Therapeutics Inc. was less bullish than Rafael Holdings Inc.
Rafael Holdings Inc. beats Aimmune Therapeutics Inc. on 8 of the 9 factors.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.
Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, focuses on the development and commercialization of oncology drugs. Rafael Holdings, Inc. is based in Newark, New Jersey.